Please login to the form below

Not currently logged in
Email:
Password:

Veltassa

This page shows the latest Veltassa news and features for those working in and with pharma, biotech and healthcare.

Real-world data finds patients feel better on Entresto, says Novartis

Real-world data finds patients feel better on Entresto, says Novartis

Lokelma (sodium zirconium cyclosilicate or ZS-9) and Vifor Pharma’s Veltassa (patiromer) which “will be a particularly valuable addition to the clinic if efficacy can be confirmed in clinical trials”.

Latest news

  • AZ gets US approval for Veltassa rival Lokelma AZ gets US approval for Veltassa rival Lokelma

    AZ gets US approval for Veltassa rival Lokelma. But GlobalData predicts Veltassa has the edge due to positive data in chronic hyperkalaemia. ... That left AZ playing catch-up in the market with Vifor’s Veltassa (patiromer), which was approved in the US

  • AZ finally gets EU nod for Veltassa rival Lokelma AZ finally gets EU nod for Veltassa rival Lokelma

    AZ finally gets EU nod for Veltassa rival Lokelma. And expects a US FDA verdict for the hyperkalaemia treatment later this year. ... challenge Vifor Pharma’s Veltassa (patiromer) which was approved in the EU last year and has been sold in the US since

  • Vifor wins European approval for Veltassa Vifor wins European approval for Veltassa

    Vifor wins European approval for Veltassa. European Commission approves the drug to treat hyperkalaemia. ... Relypsa plans to submit Veltassa applications in other markets worldwide and the product is currently under regulatory review in Switzerland and

  • FDA turns down AZ's ZS-9 once again on manufacturing issues FDA turns down AZ's ZS-9 once again on manufacturing issues

    On the plus side for AZ it seems that safety is not causing a concern for the regulator - something that resulted in rival drug Veltassa (patiromer) from Relypsa - now part of ... Veltassa was launched in early 2016 - becoming the first new drug for

  • Rare disease therapies head the ‘class of 2015’ Rare disease therapies head the ‘class of 2015’

    parathyroid hormone replacement. Shire. USA. patiromer. Veltassa. hyperkalaemia. potassium ion binder.

More from news
Approximately 2 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Deal Watch July 2016 Deal Watch July 2016

    The Vifor division, which focuses on treatments for iron deficiency, has gained a fully integrated US operation prior to the spin-out, and a complementary product in Veltassa, a potassium binder ... Veltassa was approved in late 2015 and Relypsa achieved

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

Ali Frederic Ben-Amor
Tackling a formidable foe
Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...
Geoff
Cancer care – the power of new technologies
With patient numbers set to soar, how can we make a difference?...
image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...

Infographics